The forward-looking market outlook for Ocugen, Inc. is defined by high risk and high potential reward, characteristic of clinical-stage biotechnology enterprises. Investors and analysts monitor upcoming regulatory readouts, Phase III clinical trial advancements for its gene therapy candidate OCU410 in geographic atrophy, and ongoing research and development expenditures. While bullish forecasts highlight transformative upside if its ophthalmic pipeline successfully commercializes, cautious outlooks emphasize ongoing operating losses, substantial cash burn, and the necessity of securing additional capital or strategic partnerships.